Interpharma

News

Pharma groups have held back from submitting around a third of their new medicines for reimbursement in Switzerland, impeding patient access.

News

Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.